IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias

Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)

(2015) N. D. Wagner-Johnston et al.   BLOOD

IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma

(2015) Xiaolin Wan et al.   NEOPLASIA

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

(2015) James Andrew McCubrey et al.   Oncotarget

Genome-wide Mapping and Characterization of Notch-Regulated Long Noncoding RNAs in Acute Leukemia

(2014) Thomas Trimarchi et al.   CELL

Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential

(2014) Louise M. Treanor et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice

(2014) A Staffas et al.   LEUKEMIA

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

(2014) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies

(2014) Jorge Castillo et al.   OncoTargets and Therapy

In vivo leukemogenic potential of an interleukin 7 receptor   chain mutant in hematopoietic stem and progenitor cells

(2013) K. Yokoyama et al.   BLOOD

Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia

(2013) N. Yaktapour et al.   BLOOD

Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform-selective inhibition of p110β PI3-kinase and requires blockade of all class 1 PI3K activity

(2013) Chloe Stengel et al.   BRITISH JOURNAL OF HAEMATOLOGY

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

(2013) Carolyn D. Britten   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

(2013) J. Renshaw et al.   CLINICAL CANCER RESEARCH

Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

(2013) A. Pavlicek et al.   MOLECULAR CANCER THERAPEUTICS

The genomic landscape of hypodiploid acute lymphoblastic leukemia

(2013) Linda Holmfeldt et al.   NATURE GENETICS

Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia

(2012) M. Porcu et al.   BLOOD

Targeting Nonclassical Oncogenes for Therapy in T-ALL

(2012) Prem S. Subramaniam et al.   CANCER CELL

Effects of insulin-like growth factor-1 on B-cell precursor acute lymphoblastic leukemia

(2012) Hiroyuki Yamada et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?

(2012) Andrea Gombos et al.   INVESTIGATIONAL NEW DRUGS

Defined, serum-free conditions for in vitro culture of primary human T-ALL blasts

(2012) A J Yost et al.   LEUKEMIA

Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL

(2012) Samuel Gusscott et al.   LEUKEMIA RESEARCH

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

(2012) Jinghui Zhang et al.   NATURE

NOTCH1 promotes T cell leukemia-initiating activity by RUNX-mediated regulation of PKC-θ and reactive oxygen species

(2012) Vincenzo Giambra et al.   NATURE MEDICINE

PI3K signalling: the path to discovery and understanding

(2012) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Suppressors of Cytokine Signaling (SOCS) Proteins and JAK/STAT Pathways

(2011) Taiga Tamiya et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

IL-7 Contributes to the Progression of Human T-cell Acute Lymphoblastic Leukemias

(2011) A. Silva et al.   CANCER RESEARCH

High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling

(2011) Hind Medyouf et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Gain-of-function mutations ininterleukin-7 receptor-α(IL7R) in childhood acute lymphoblastic leukemias

(2011) Chen Shochat et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

(2011) Priscila P Zenatti et al.   NATURE GENETICS

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

(2009) A. Gutierrez et al.   BLOOD

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody

(2009) N. Chapuis et al.   HAEMATOLOGICA

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

(2009) J. M. Carboni et al.   MOLECULAR CANCER THERAPEUTICS

Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells

(2009) Amit J Sabnis et al.   PLOS BIOLOGY

Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras–initiated leukemia

(2008) Mark Y. Chiang et al.   JOURNAL OF CLINICAL INVESTIGATION

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

(2008) Ana Silva et al.   JOURNAL OF CLINICAL INVESTIGATION

Class I PI3K in oncogenic cellular transformation

(2008) L Zhao et al.   ONCOGENE